Homepage
Healthcare · Biotechnology · United States · Updated May 11, 1:55pm
$14.15
Price
$74.8M
Market Cap
15
Employees
-1.10
Beta
Stephen Uden
CEO
Business Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Business History
Price Overview
Last updated: May 11, 2026 1:55pm (just now)$14.15
-0.24 (-1.63%)
Day Range
$14.00 – $14.25
52-Week Range
$2.16 – $15.31
50-Day MA
$9.52
200-Day MA
$6.10
Volume
64,528.15
Share Structure
Outstanding
5,289,675.00
Float
3,150,954.00
Free Float
59.6%
Normal free float
— 59.6% of shares trade freely, ~40.4% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (3.2M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-8.90
Stock Price: $14.15
EPS (Diluted): -1.59
EPS (Diluted): -1.59
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.53
Stock Price: $14.15
Total Equity: $57.96M
Shares: 5,629,370
Total Equity: $57.96M
Shares: 5,629,370
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.32
Market Cap: $74.82M
Total Debt: $176,000
Cash: $31.37M
EBITDA: -$27.97M
Total Debt: $176,000
Cash: $31.37M
EBITDA: -$27.97M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$-292,759
Market Cap: $74.82M
Total Debt: $176,000
Cash: $31.37M
Total Debt: $176,000
Cash: $31.37M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
89.3%
Gross Profit: $766,000
Revenue: $858,000
Revenue: $858,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-3,270.9%
Operating Income: -$28.06M
Revenue: $858,000
Revenue: $858,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1,046.4%
Net Income: -$8.98M
Revenue: $858,000
Revenue: $858,000
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-16.2%
Net Income: -$8.98M
Total Equity: $57.96M
Total Equity: $57.96M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-56.9%
Operating Income: -$28.06M
Tax Rate: 0.0%
Equity: $57.96M
Total Debt: $176,000
Cash: $31.37M
Tax Rate: 0.0%
Equity: $57.96M
Total Debt: $176,000
Cash: $31.37M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
14.50
Current Assets: $61.25M
Current Liabilities: $4.22M
Current Liabilities: $4.22M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $94,000
Long-Term Debt: $82,000
Total Debt: $176,000
Total Equity: $57.96M
Long-Term Debt: $82,000
Total Debt: $176,000
Total Equity: $57.96M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.15
Revenue: $858,000
Shares: 5,629,370
Shares: 5,629,370
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$10.30
Total Equity: $57.96M
Shares: 5,629,370
Shares: 5,629,370
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-5.30
Operating CF: -$29.81M
CapEx: $0.00
Shares: 5,629,370
CapEx: $0.00
Shares: 5,629,370
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $14.15
Stock Price: $14.15
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$8.98M
Net Income: -$8.98M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares RLYB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $636,000 | $858,000 |
| Cost of Revenue | $109,000 | $167,000 | $150,000 | $0 | $92,000 |
| Gross Profit | $-109,000 | $-167,000 | $-150,000 | $636,000 | $766,000 |
| Operating Expenses | $45.6M | $67.9M | $78.9M | $61.1M | $28.8M |
| Operating Income | -$45.6M | -$67.9M | -$78.9M | -$60.5M | -$28.1M |
| Net Income | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$9.0M |
| EBITDA | -$45.4M | -$67.7M | -$78.8M | -$60.4M | -$28.0M |
| EPS | $-11.68 | $-16.72 | $-14.72 | $-10.64 | $-1.59 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $175.3M | $57.0M | $24.5M | $13.9M | $31.4M |
| Total Current Assets | $180.9M | $179.5M | $114.8M | $67.8M | $61.3M |
| Total Assets | $182.2M | $180.4M | $115.6M | $68.1M | $62.3M |
| Current Liabilities | $6.6M | $10.7M | $9.3M | $6.2M | $4.2M |
| Long-Term Debt | $0 | $374,000 | $0 | $0 | $82,000 |
| Total Liabilities | $6.6M | $11.1M | $9.4M | $6.5M | $4.3M |
| Total Equity | $175.6M | $169.3M | $106.2M | $61.7M | $58.0M |
| Retained Earnings | -$94.0M | -$160.7M | -$235.2M | -$293.0M | -$302.0M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$45.5M | -$57.3M | -$60.3M | -$49.3M | -$29.8M |
| Capital Expenditure | $-333,000 | $-54,000 | $-12,000 | $0 | $0 |
| Free Cash Flow | -$45.9M | -$57.3M | -$60.3M | -$49.3M | -$29.8M |
| Acquisitions (net) | -$2.0M | $-300,000 | -$2.3M | -$2.0M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $35.1M | -$118.4M | -$32.5M | -$10.6M | $17.5M |
Analyst Estimates (Annual)
| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$80,000 $80,000 – $80,000
|
$87.9M $87.9M – $87.9M
|
$87.5M $87.5M – $87.5M
|
$89.0M $89.0M – $89.0M
|
| EBITDA |
$15,999 $15,999 – $15,999
|
$17.6M $17.6M – $17.6M
|
$17.5M $17.5M – $17.5M
|
$17.8M $17.8M – $17.8M
|
| Net Income |
-$31.1M -$31.1M – -$31.1M
|
-$64.9M -$64.9M – -$64.9M
|
-$17.6M -$17.6M – -$17.6M
|
$22.1M $22.1M – $22.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | +34.9% |
| Gross Profit Growth | -53.2% | +10.2% | +524.0% | +20.4% |
| Operating Income Growth | -48.7% | -16.3% | +23.4% | +53.6% |
| Net Income Growth | -41.8% | -11.9% | +22.5% | +84.5% |
| EBITDA Growth | -49.2% | -16.3% | +23.4% | +53.7% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-05 | ADAR1 Capital Management, LLC | P-Purchase | 35,101.00 | $14.00 | $491,260 |
| 2026-05-04 | ADAR1 Capital Management, LLC | P-Purchase | 116,904.00 | $13.97 | $1.6M |
| 2026-05-04 | ADAR1 Capital Management, LLC | P-Purchase | 3,900.00 | $13.90 | $54,201 |
| 2026-05-04 | ADAR1 Capital Management, LLC | 0.00 | $0.00 | $0 | |
| 2026-03-04 | FMR LLC | 0.00 | $0.00 | $0 | |
| 2026-02-18 | Lieber Jonathan I | A-Award | 2,500.00 | $0.00 | $0 |
| 2026-02-23 | Lieber Jonathan I | S-Sale | 789.00 | $5.06 | $3,992 |
| 2026-02-18 | MACKAY MARTIN | A-Award | 18,055.00 | $4.45 | $80,345 |
| 2026-02-18 | HUNT RONALD | A-Award | 14,305.00 | $4.45 | $63,657 |
| 2025-05-13 | Boudreau Helen M | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-05-13 | Chung Wendy | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-05-13 | HUNT RONALD | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-05-13 | Nash Christine A | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-05-13 | Hopfner Robert Lorne | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-05-13 | Soteropoulos Paula | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-05-13 | Liu Hui | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-05-13 | MACKAY MARTIN | A-Award | 28,500.00 | $0.30 | $8,550 |
| 2025-02-14 | Uden Stephen | A-Award | 453,700.00 | $0.76 | $344,812 |
| 2025-02-14 | Ryder Steven | A-Award | 180,000.00 | $0.76 | $136,800 |
| 2025-02-14 | Lieber Jonathan I | A-Award | 180,000.00 | $0.76 | $136,800 |
No community reviews yet for RLYB.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27